HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Historical Holders from Q1 2014 to Q3 2025

Symbol: HRTX on Nasdaq
Type / Class: Equity / Common Stock, par value $0.01 per share
Shares outstanding: 183,255,226
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 152,658,767
Holdings value: $192,362,843
% of all portfolios: 0%
Number of holders: 171
Number of buys: 73
Number of sells: -68
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Rubric Capital Management LP	15.9%	-8.9%	$37,859,003	+$1,192,086	30,046,828	+3.3%	Rubric Capital Management LP	15 Oct 2025
Clearline Capital LP	5.3%		$11,655,032		9,712,527		Clearline Capital LP	30 Sep 2025
VANGUARD GROUP INC	4.61%		$10,659,328		8,459,784		The Vanguard Group	30 Sep 2025

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	152,658,767	$192,362,843	+$22,498,799	$2,668,554	$25,326	$1.26	171
2025 Q2	131,463,843	$272,131,676	+$12,999,478	$56,097	$3,233,754	$2.07	170
2025 Q1	124,770,231	$274,489,898	+$21,979,195	$104,940	$1,864,060	$2.2	164
2024 Q4	114,941,581	$175,829,179	-$13,146,397	$49,362	$3,059,388	$1.53	161
2024 Q3	121,816,811	$242,421,216	-$29,164,536	$188,851	$159,996	$1.99	169
2024 Q2	129,609,461	$453,638,008	+$35,415,047	$516,950	$331,450	$3.5	189
2024 Q1	119,262,673	$330,361,469	+$19,698,437	$285,310	$417,162	$2.77	157
2023 Q4	112,451,511	$191,165,565	+$1,074,277	$133,960	$386,410	$1.7	149
2023 Q3	118,378,841	$121,934,068	+$19,982,956	$6,077	$11,639	$1.03	138
2023 Q2	98,652,577	$114,435,495	-$11,706,623	$58,580	$19,024	$1.16	143
2023 Q1	107,852,430	$162,855,915	-$15,688,602	$30,804	$12,382	$1.51	153
2022 Q4	115,831,665	$289,582,111	-$29,877,564	$124,250	$2,593,750	$2.5	175
2022 Q3	121,963,764	$514,346,608	+$45,998,596	$239,000	$507,000	$4.22	178
2022 Q2	115,204,514	$321,404,107	+$4,826,591	$187,000	$856,000	$2.79	160
2022 Q1	108,535,070	$620,478,626	-$95,435,236	$2,088,652	$7,110,100	$5.72	176
2021 Q4	117,646,567	$1,073,655,355	+$78,398,633	$9,833,518	$12,277,249	$9.13	192
2021 Q3	108,488,554	$1,160,926,758	+$41,634,303	$1,283,000	$2,208,000	$10.69	189
2021 Q2	103,864,409	$1,612,145,175	+$202,378,763	$3,163,000	$4,246,000	$15.52	182
2021 Q1	89,846,972	$1,456,395,898	-$11,223,795	$3,396,000	$14,408,000	$16.21	186
2020 Q4	90,262,699	$1,910,380,366	+$26,526,144	$988,000	$2,362,000	$21.16	180
2020 Q3	90,857,946	$1,346,585,988	+$33,105,054	$645,000	$333,000	$14.82	177
2020 Q2	88,614,685	$1,334,393,703	-$51,210,796	$4,339,000	$2,571,000	$14.71	185
2020 Q1	92,095,623	$1,081,183,715	-$131,875,186	$7,371,000	$3,363,000	$11.74	186
2019 Q4	99,047,059	$2,326,444,060	+$183,809,453	$3,806,000	$4,082,000	$23.5	194
2019 Q3	91,435,188	$1,691,767,958	-$43,730,310	$5,187,000	$6,977,000	$18.5	175
2019 Q2	93,875,302	$1,744,712,239	+$2,233,456	$6,179,000	$6,654,000	$18.59	170
2019 Q1	92,662,760	$2,264,521,795	+$28,820,026	$7,559,000	$43,909,000	$24.44	189
2018 Q4	91,350,119	$2,369,031,974	+$92,438,916	$3,566,000	$5,989,000	$25.94	169
2018 Q3	87,463,202	$2,768,171,136	+$131,977,881	$5,757,000	$19,334,000	$31.65	187
2018 Q2	77,152,541	$2,997,578,965	+$216,890,926	$88,982,000	$33,827,000	$38.85	192
2018 Q1	72,567,037	$2,001,875,074	+$342,791,800	$32,734,000	$36,506,000	$27.6	149
2017 Q4	60,500,377	$1,095,067,241	+$103,341,807	$2,416,000	$13,480,000	$18.1	120
2017 Q3	63,406,329	$1,024,008,242	-$88,424,754	$1,536,000	$10,975,000	$16.15	101
2017 Q2	69,617,065	$964,195,934	+$47,548,351	$1,017,000	$23,489,000	$13.85	102
2017 Q1	71,661,852	$1,074,958,781	+$337,458,954	$1,472,000	$1,260,000	$15	98
2016 Q4	52,666,446	$689,938,271	+$4,719,852	$7,670,000	$20,264,000	$13.1	94
2016 Q3	51,265,727	$883,246,939	+$71,930,213	$6,967,000	$11,736,000	$17.23	88
2016 Q2	46,993,886	$848,220,501	+$35,391,534	$3,429,000	$12,412,000	$18.05	90
2016 Q1	45,017,464	$854,951,019	-$8,625,778	$7,874,000	$12,121,000	$18.99	98
2015 Q4	45,438,610	$1,214,308,493	+$39,761,438	$2,415,000	$32,428,000	$26.7	103
2015 Q3	43,669,932	$1,064,954,183	+$173,790,187	$32,055,000	$102,594,000	$24.4	101
2015 Q2	36,118,773	$1,125,171,985	+$319,523,410	$2,225,000	$69,154,000	$31.16	86
2015 Q1	26,445,484	$384,782,059	+$31,452,121	$426,000	$12,094,000	$14.55	68
2014 Q4	24,573,735	$247,206,453	+$2,536,942		$851,000	$10.06	62
2014 Q3	24,229,222	$201,828,829	-$7,802,513			$8.33	56
2014 Q2	26,551,442	$327,060,299	+$69,901,807			$12.32	67
2014 Q1	20,801,929	$289,178,683	+$283,529,683			$13.91	39